Business
Redcare Pharmacy Confirms Full-year Guidance Following Sustained Positive Q3 Sales Performance in Both Rx and Non-Rx
Total sales up 25% to EUR 719M in Q3. YTD total sales up 27% or EUR 450M to EUR 2.15bn. Non-Rx sales up 17% to EUR 448M in Q3; YTD 18% to EUR 1.4bn. Rx sales in Germany up 82% to EUR 126M in Q3, YTD 122% and EUR 348M. Number of active custome...
About this update from Redcare Pharmacy N.v.
[{"type":"table","headerItems":[],"items":[{"val":[{"val":[{"type":"list","items":[{"val":[{"type":"text","content":"Total sales up 25% to EUR 719M in Q3. ","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"YTD total sales up 27% or EUR 450M to EUR 2.15bn. ","length":49,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-Rx sales up 17% to EUR 448M in Q3; YTD 18% to EUR 1.4bn. ","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Rx sales in Germany up 82% to EUR 126M in Q3, YTD 122% and EUR 348M.","length":68,"tagName":"p"}]},{"val":[{"type":"text","content":"Number of active customers up 0.2M, reaching 13.7M. NPS up, to well over 70.","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"Company reaffirms all elements of full-year guidance.","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false},{"type":"text","content":"SEVENUM, THE NETHERLANDS - October 6, 2025 (NEWMEDIAWIRE) - Redcare Pharmacy N.V. today announced its preliminary and unaudited third quarter sales numbers. The Group's total sales increased 25.2% to EUR 719 million (Q3 2024: EUR 575 million). Both reporting segments, DACH and International, achieved over 25% fully organic sales growth in Q3, 25.2% and 25.4% respectively. Non-Rx sales increased 16.7% to EUR 448 million (Q3 2024: EUR 383 million) and total Rx sales 42.3% to EUR 272 million (Q3 2024: EUR 191 million). In Germany, Rx sales totaled EUR 126 million, an increase of 82.1% year over year (Q3 2024: EUR 69 million). At the end of the quarter, Redcare Pharmacy recorded 13.7 million active customers and a significant improvement in the net promoter score (NPS) to well over 70, vs. 64 in H1 of the current year.","length":830,"tagName":"p"},{"type":"text","content":"Redcare Pharmacy's CEO Olaf Heinrich comments: "We are delivering strong Q3 momentum, especially in German Rx where we grew double-digits quarter over quarter, and confirm full-year guidance. Growth remains profitable and cash generative, with a solid Q3 EBITDA, lifting our year-to-date margin already to our full-year guidance range of 2 to 2.5%."","length":363,"tagName":"p"},{"type":"text","content":"Strong momentum in Rx. ","length":22,"tagName":"p"},{"type":"text","content":"Entering Q4 with accelerated Rx growth in Germany and the customary seasonal uplift in order volumes in ...